Sustained release of brimonidine from BRI@SR@TPU implant for treatment of glaucoma
Sign Up to like & getrecommendations! Published in 2022 at "Drug Delivery"
DOI: 10.1080/10717544.2022.2039806
Abstract: Abstract Glaucoma is the leading cause of irreversible vision loss worldwide, and reduction of intraocular pressure (IOP) is the only factor that can be interfered to delay disease progression. As the first line and preferred… read more here.
Keywords: glaucoma; release; bri tpu; bri ... See more keywords